Novartis Finland Oy, Espoo, Finland.
Auria Biobank, University of Turku and Turku University Hospital, Turku, Finland.
ESC Heart Fail. 2019 Aug;6(4):603-612. doi: 10.1002/ehf2.12443. Epub 2019 May 3.
The aims of this study were to describe patient characteristics of the adult chronic heart failure (HF) population and to estimate the prevalence, incidence, healthcare resource utilization (HCRU), and mortality associated with HF in Southwest Finland.
This was a retrospective biobank and clinical registry study. Adult patients with an HF diagnosis (International Statistical Classification of Diseases and Related Health Problems (ICD) code I50) during 2004-2013 in secondary care were included in the study and compared with age-matched and gender-matched control patients without an I50 diagnosis. HF patients were stratified in groups by left ventricular ejection fraction (LVEF) as follows: LVEF < 40% [HF with reduced ejection fraction (HFrEF)]; LVEF ≥ 40% [HF with preserved ejection fraction (HFpEF)]; or unknown (LVEF unknown). HCRU was stratified by inpatient, outpatient, and emergency room visits. In 2013, the incidence of HF was 3.2/1000, and the prevalence was 13.9/1000 inhabitants (n = 15 594). In the stratified analysis of HF patients (n = 8833, average ± SD age 77.1 ± 11.2), 1115 (12.6%) patients had HFrEF (female 31.3%), 1449 (16.4%) had HFpEF (female 50.9%), and 6269 (71%) had unknown LVEF (female 52.1%). The most common co-morbidities were essential hypertension (58%), chronic elevated serum creatinine (57.3%), atrial fibrillation and flutter (55.1%), and chronic ischaemic heart disease (46.4%). Patients with HF diagnosis had higher HCRU compared with that of age-matched and gender-matched controls (3.7 more days per year at the hospital for HF patients compared with the controls). The total 5 year mortality was 62.6% for HF patients and 28.3% for controls, with higher age being the strongest predictor of mortality. Moreover, multivariable Cox regression analysis showed that patients with HFrEF had a 13% (95% confidence interval 2.7-25%) increased risk of mortality compared with HFpEF patients.
The high mortality rate and HCRU among the studied HF patients highlight the severity of the disease and the economic and social burden on both patients and society. This calls for improved methods of care for this large patient population.
本研究旨在描述成年慢性心力衰竭(HF)患者的特征,并估计芬兰西南部 HF 的患病率、发病率、医疗资源利用(HCRU)和死亡率。
这是一项回顾性生物库和临床登记研究。纳入了 2004-2013 年在二级医疗机构中诊断为 HF(国际疾病分类第十次修订版(ICD)编码 I50)的成年患者,并与年龄和性别匹配的无 I50 诊断的对照组患者进行比较。根据左心室射血分数(LVEF)将 HF 患者分为以下组:LVEF<40%[射血分数降低的心力衰竭(HFrEF)];LVEF≥40%[射血分数保留的心力衰竭(HFpEF)];或未知(LVEF 未知)。HCRU 按住院、门诊和急诊就诊分层。2013 年 HF 的发病率为 3.2/1000,患病率为 13.9/1000 居民(n=15594)。在 HF 患者(n=8833,平均年龄±标准差为 77.1±11.2)的分层分析中,1115 例(12.6%)患者为 HFrEF(女性 31.3%),1449 例(16.4%)为 HFpEF(女性 50.9%),6269 例(71%)为 LVEF 未知(女性 52.1%)。最常见的合并症是原发性高血压(58%)、慢性血清肌酐升高(57.3%)、心房颤动和扑动(55.1%)和慢性缺血性心脏病(46.4%)。与年龄和性别匹配的对照组相比,HF 诊断患者的 HCRU 更高(HF 患者每年住院天数比对照组多 3.7 天)。HF 患者的 5 年总死亡率为 62.6%,对照组为 28.3%,年龄较大是死亡的最强预测因素。此外,多变量 Cox 回归分析显示,与 HFpEF 患者相比,HFrEF 患者的死亡率增加了 13%(95%置信区间 2.7-25%)。
研究中 HF 患者的高死亡率和 HCRU 突出了疾病的严重性以及对患者和社会的经济和社会负担。这需要改进对这一大患者群体的护理方法。